https://orcid.org/0000-0001-5285-8939
References
- Vaishnavi A , LeAT , DoebeleRC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov.5, 25–34 (2015).
- Okamura R , BoichardA , KatoSet al. Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics. JCO Precis. Oncol.2018, PO.18.00183 (2018).
- Hibar DP , DemetriGD , PetersSet al. Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors. PLOS ONE17, e0270571 (2022).
- Harada G , DrilonA. TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults. Cancer Genet.264–265, 33–39 (2022).
- Drilon A , LaetschTW , KummarSet al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N. Engl. J. Med.378, 731–739 (2018).
- Doebele R , DrilonA , Paz-AresLet al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol.21, 271–282 (2020).
- Böhm R , von HehnL , HerdegenTet al. OpenVigil FDA – inspection of U.S. American adverse drug events pharma covigilance data and novel clinical applications. PLOS ONE11, e0157753 (2016).
- Nair HP , KulkarniAR , EswaranM , SubeeshV. Pantoprazole associated dyspepsia hypocalcemia and hyponatremia: a disproportionality analysis in FDA Adverse Event Reporting System (FAERS) database. Arab. J. Gastroenterol.24, 1–4 (2023).
- Bate A . Bayesian Confidence Propagation Neural Network. Drug Saf.30, 623–625 (2007).
- Kappers MHW , van EschJHM , SluiterWet al. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension56, 675–681 (2010).
- El-Nassan HB , Al-QadhiMA. Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: a mini review. Eur. J. Med. Chem.258, 115618 (2023).
- Roviello G , D’AngeloA , SciortinoMet al. TRK fusion positive cancers: from first clinical data of a TRK inhibitor to future directions. Crit. Rev. Oncol. Hematol.152, 103011 (2020).
- Moriyama E , NagasuS , TanakaTet al. Case report: a case of complete response to entrectinib in NTRK fusion gene-positive parotid gland cancer. Front. Oncol.13, 1247435 (2023).
- Recine F , DeVita A , FaustiVet al. Case report: adult NTRK-rearranged spindle cell neoplasm: early tumor shrinkage in a case with bone and visceral metastases treated with targeted therapy. Front. Oncol.11, 740676 (2022).
- Wu S , LiuY , ShiX , ZhouW , ZengX. Elaboration of NTRK-rearranged colorectal cancer: integration of immunoreactivity pattern, cytogenetic identity, and rearrangement variant. Dig. Liver Dis.S1590-8658(23), 00578–9 (2023).
- Zhang D , LiaoX. Pan-TRK immunohistochemistry and NTRK gene fusions in primary carcinomas of the liver. AIMM30, 435–440 (2022).
- Drilon A , NagasubramanianR , BlakeJFet al. A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors. Cancer Discov.7, 963–972 (2017).
- Cocco E , LeeJE , KannanSet al. TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors. Cancer Discov.11, 126–141 (2021).
- Bagal SK , OmotoK , BlakemoreDCet al. Discovery of allosteric, potent, subtype selective, and peripherally restricted TrkA kinase inhibitors. J. Med. Chem.62, 247–265 (2019).